Oystein Soug
Chief Executive Officer Oncoinvent AS
Oystein Soug has served as CEO of clinical-stage radiopharmaceutical company Oncoinvent since 2024, leading the company’s Phase 2 development of alpha-emitting radiopharmaceuticals for cancer that have spread to the abdominal cavity. Prior to joining Oncoinvent, he was CEO of Calluna Pharma (previous Arxx Therapeutics) and Circio (previous Targovax). Earlier in his career, Mr. Soug served as CFO of Oslo-listed radiopharmaceutical company Algeta, where he played a key role in the company’s growth and commercialization journey. During his tenure, Algeta successfully launched and completed its Phase 3 trial, launched the radium-223 therapy Xofigo® for prostate cancer, and entered into a strategic commercialization partnership. He later co-led the sale of Algeta to Bayer for USD 3bn. Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen, Switzerland.
Seminars
- Sharing Phase I clinical findings and evaluating the key efficacy, safety and translational signals emerging from early development
- Understanding how early clinical data can be used to refine patient selection, endpoint strategy and study design ahead of Phase II
- Exploring the operational, clinical and regulatory challenges associated with progressing a radiopharmaceutical programme beyond first-in-human evaluation
